{"id":"W2336389733","doi":"10.1200/jco.2006.24.18_suppl.13100","title":"Synergistic inhibition of breast cancer cell lines with the combination of a dual inhibitor of EGFR/HER-2/neu and a Bcl-2 inhibitor","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Lapatinib; Erlotinib; Tyrosine-kinase inhibitor; Cancer research; Hsp90 inhibitor; Trastuzumab; SKBR3; EGFR inhibitors; Medicine; Apoptosis; Breast cancer; ErbB; Epidermal growth factor receptor; Transfection; Growth inhibition; MTT assay; Cell culture; Pharmacology; Cancer; Internal medicine; Biology; Hsp90; Heat shock protein; Human breast; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001928055,0.0004559109,0.0004725041,0.0003243864,0.0001308906,0.0002795474,0.0003527621,0.0002811278,0.001705514],"category_scores_gemma":[0.00008028735,0.0001573333,0.0003870167,0.0003107835,0.0001459604,0.000192599,0.0002089998,0.0005484965,0.0004275841],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003104252,"about_ca_system_score_gemma":0.0003903224,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007284536,"about_ca_topic_score_gemma":0.002472575,"domain_scores_codex":[0.9998368,0.00003258251,0.00001471034,0.00002472674,0.00005233014,0.00003882731],"domain_scores_gemma":[0.9999348,0.00001579163,0.000009840598,0.000008983341,0.000009156303,0.00002140168],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001704311,0.001236314,0.0006510243,0.0002529929,0.00009344486,0.0001285172,0.00005678793,0.0005877054,0.9789251,0.0002745374,0.001152485,0.01493668],"study_design_scores_gemma":[0.0005096181,0.007767607,0.005623261,0.0000206268,0.0001323848,0.0005084947,0.00006075148,0.002763313,0.9725427,0.00005644997,0.009996101,0.00001861974],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874058,0.004574724,0.001442428,0.0001910882,0.0001828843,0.0001906559,0.0005722191,0.0001636699,0.005276411],"genre_scores_gemma":[0.990669,0.002256358,0.002929856,0.0001004287,0.00002894863,0.000155237,0.0007627378,0.00001435471,0.003083099],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001705514,"threshold_uncertainty_score":0.005705535,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06359530791566989,"score_gpt":0.4369986087786727,"score_spread":0.3734033008630029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}